Skip to main content

Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug

Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion, HutchMed will also pay royalties on net sales.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.